Article Contents ::
- 1 The Brand Name MEZALOG Has Generic Salt :: OXCARBAZEPINE
- 2 MEZALOG Is From Company LA DRUG Priced :: Rs. 49
- 3 MEZALOG have OXCARBAZEPINE is comes under Sub class Anti Epileptics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MEZALOG Has Generic Salt :: OXCARBAZEPINE
MEZALOG Is From Company LA DRUG Priced :: Rs. 49
MEZALOG have OXCARBAZEPINE is comes under Sub class Anti Epileptics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Epileptics
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| OXCARBAZEPINE | TAB | Rs. 49 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| MEZALOG | LA DRUG | 300MG | 10 | Rs. 49 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From LA DRUG :: MEZALOG | OXCARBAZEPINE | Nervous System | Anti Epileptics |
Indications for Drugs ::
Partial seizures, Generalised tonic-clonic seizures
Drug Dose ::
Oral Monotherapy or adjunctive therapy in the treatment of partial seizures with or without secondary generalised tonic-clonic seizures Adult: Initially, 600 mg daily in 2 divided doses; increase at a max increments of 600 mg daily at wkly intervals depending on response. Maintenance: 600-1,200 mg daily. Adjunctive therapy/refractory patients switched from other anticonvulsants: Up to 2,400 mg daily. Child: >6 yr: 8-10 mg/kg daily in 2 divided doses; increase as necessary to max increments of 10 mg/kg daily at about wkly intervals to a max of 46 mg/kg daily. Maintenance in adjunctive therapy: 30 mg/kg daily. Renal impairment: CrCl (ml/min) <30 Initially, 300 mg daily or 50% of usual dose. Increase at wkly intervals or longer. Contraindication ::
Hypersensitivity. Lactation.
Drug Precautions ::
Cross-sensitivity to carbamazepine may occur. Do not discontinue abruptly. Renal and hepatic impairment. Patients at risk of hyponatraemia. May impair ability to drive or operate machinery. Pregnancy.
Drug Side Effects ::
Dizziness, somnolence, headache, ataxia, fatigue, vertigo, nervousness, amnesia, abnormal thinking, insomnia, speech disorder, agitation, confusion; vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, constipation, gastritis, wt gain; abnormal gait, tremor, weakness, back pain, abnormal coordination, dysmetria, sprains/strains, muscle weakness; diplopia, nystagmus, abnormal vision and accommodation; hypotension, leg oedema; rash, acne; hyponatraemia; rhinitis, chest infection, epistaxis, sinusitis. Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis. Anaphylaxis and angioedema.
Pregnancy category ::
3
Drug Mode of Action ::
Oxcarbazepine blocks voltage-sensitive sodium channels, which inhibits repetitive firing, stabilises hyperexcited neuronal membranes and decreases release of synaptic impulses. These effects may prevent the spread of epileptic seizures.
Drug Interactions ::
Reduced serum levels with carbamazepine, phenobarbitone, phenytoin, valproic acid. May reduce levels/effects of CYP3A4 substrates (e.g. benzodiazepines, calcium channel blockers, clarithromycin, ciclosporin, erythromycin, oestrogens, mirtazapine, nateglinide, nefazodone, nevirapine, protease inhibitors, tacrolimus, venlafaxine). May reduce efficacy of oral contraceptives. May reduce levels/effects of maraviroc. May increase levels of phenobarbitone, phenytoin.
